PET/CT imaging and dosimetry as predictive factors for treatment response of the 177Lu-DOTA-TATE therapy - DOTADOSE
Latest Information Update: 22 Jan 2019
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- Acronyms DOTADOSE
- 26 Nov 2012 New trial record